These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22818843)

  • 1. Diaphragmatic rupture, a new complication of Bevacizumab.
    Lacaze L; Scotté M
    Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
    Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
    J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
    August DA; Serrano D; Poplin E
    J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
    Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
    Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer.
    Hompes D; Ruers T
    Eur J Surg Oncol; 2011 Sep; 37(9):737-46. PubMed ID: 21764243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-induced bowel perforation.
    Sliesoraitis S; Tawfik B
    J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and radiological response with FOLFOXIRI and bevacizumab as third-line therapy after mFOLFOX6 and FOLFIRI failure.
    de Melo JV; Vieira de Melo MS; Abad MH
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S19-20. PubMed ID: 21768793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer.
    Thornton AD; Ravn P; Winslet M; Chester K
    Br J Surg; 2006 Dec; 93(12):1456-63. PubMed ID: 17115389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trials of bevacizumab in breast cancer--a safety review.
    Kümler I; Nielsen DL
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S37-48. PubMed ID: 21663533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy.
    Burkart CM; Grisel JJ; Hom DB
    Laryngoscope; 2008 Sep; 118(9):1539-41. PubMed ID: 18622319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
    Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed bile leak with avastin after liver resection for metastatic colorectal cancer.
    Lordan JT; Wilkins M; Karanjia ND
    Hepatogastroenterology; 2011; 58(110-111):1769-70. PubMed ID: 22086700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in lung cancer: lackluster performance and unjustified expense?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Sep; 18(3):381-2. PubMed ID: 22777997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient.
    Berk V; Ismailogullari S; Donmez H; Karaca H; Inanc M; Ozkan M
    Med Oncol; 2012 Jun; 29(2):1017-9. PubMed ID: 21461780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and severe acne in a patient treated with bevacizumab.
    Molina-Ruiz AM; Domine M; Requena L
    Int J Dermatol; 2013 Apr; 52(4):486-90. PubMed ID: 23432695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GI perforation associated with bevacizumab.
    Yoon SS; Rivera R; Shah A; Ozden N
    Gastrointest Endosc; 2012 Jun; 75(6):1286-7. PubMed ID: 21862004
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
    Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab: overview of the literature.
    Braghiroli MI; Sabbaga J; Hoff PM
    Expert Rev Anticancer Ther; 2012 May; 12(5):567-80. PubMed ID: 22594892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.